Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02386800 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CINC424A2X01B Rollover Protocol

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years 6 months later Sep 16, 2027 → Apr 5, 2032
See other at-risk trials from Novartis

Record History

The 50 most recent of 107 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 16, 2027 to Apr 5, 2032 Secondary endpoints revised (2) · Site details revised at 4 of 97 sitesv107 Show 2 more changesShow less
    • Secondary endpoints revised (2)
    • Site details revised at 4 of 97 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status changed: Recruiting → Active, Not Recruiting Trial sites reduced: 101 → 97 locations · Enrollment target: estimated 296 to confirmed 279v106 Show 2 more changesShow less
    • Trial sites reduced: 101 → 97 locations
    • Enrollment target: estimated 296 to confirmed 279
  3. Trial status changed: Active, Not Recruiting → Recruiting Trial sites expanded: 97 → 101 locations · Completion pushed from Sep 16, 2027 to Apr 5, 2032 · Enrollment target: 279 to 296v105 Show 3 more changesShow less
    • Trial sites expanded: 97 → 101 locations
    • Completion pushed from Sep 16, 2027 to Apr 5, 2032
    • Enrollment target: 279 to 296
  4. Site details revised at 3 of 97 sitesv104
  5. Site details revised at 10 of 97 sitesv103
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 98 to 97v102
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 356 to confirmed 279 · Study sites: 102 to 98v101 Show 2 more changesShow less
    • Enrollment target: estimated 356 to confirmed 279
    • Study sites: 102 to 98
  3. Trial status: Active, Not Recruiting to Recruiting Enrollment target: 279 to 356 · Study sites: 97 to 102v100 Show 2 more changesShow less
    • Enrollment target: 279 to 356
    • Study sites: 97 to 102
  4. Re-verified, no change to tracked fieldsv99
  5. Site details revised at 1 of 97 sitesv98
  6. 4 versions Re-verified since Feb 11, 2025, no change to tracked fieldsv94-v97
  7. Study sites: 71 to 97v93
  8. Study sites: 97 to 71v92
  9. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 356 to confirmed 279 · Study sites: 100 to 97v91 Show 2 more changesShow less
    • Enrollment target: estimated 356 to confirmed 279
    • Study sites: 100 to 97
  10. Study sites: 99 to 100v90
  11. Study sites: 98 to 99v89
  12. Site details revised at 2 of 98 sitesv88
  13. Site details revised at 3 of 98 sitesv87
  14. Site details revised at 1 of 98 sitesv86
  15. Study sites: 99 to 98v85
  16. Study sites: 100 to 99v84
  17. Site details revised at 4 of 100 sitesv83
  18. Site details revised at 1 of 100 sitesv82
  19. Site details revised at 1 of 100 sitesv81
  20. Study sites: 101 to 100v80
  21. Site details revised at 5 of 101 sitesv79
  22. Site details revised at 4 of 101 sitesv78
  23. Site details revised at 1 of 101 sitesv77
  24. Re-verified, no change to tracked fieldsv76
  25. Site details revised at 2 of 101 sitesv75
  26. Site details revised at 4 of 101 sitesv74
  27. Site details revised at 4 of 101 sitesv73
  28. Study sites: 100 to 101v72
  29. Site details revised at 2 of 100 sitesv71
  30. Site details revised at 1 of 100 sitesv70
  31. Site details revised at 1 of 100 sitesv69
  32. Study sites: 99 to 100v68
  33. Site details revised at 2 of 99 sitesv67
  34. Study sites: 97 to 99v66
  35. Enrollment target: 298 to 356v65
  36. Study sites: 98 to 97v64
  37. Site details revised at 1 of 98 sitesv63
  38. Enrollment target: 356 to 298 Site details revised at 4 of 98 sitesv62 Show 1 more changeShow less
    • Site details revised at 4 of 98 sites
  39. Site details revised at 1 of 98 sitesv61
  40. Primary endpoint revised Study sites: 97 to 98 · Interventions: ruxolitinib tablets or oral pediatric formulation (Drug), ruxolitinib tablets or oral pediatric formulation, panobinostat capsules (Drug) to panobinostat (Drug), ruxolitinib (Drug) · Eligibility criteria shortened, about 713 words · 3 morev60 Show 6 more changesShow less
    • Study sites: 97 to 98
    • Interventions: ruxolitinib tablets or oral pediatric formulation (Drug), ruxolitinib tablets or oral pediatric formulation, panobinostat capsules (Drug) to panobinostat (Drug), ruxolitinib (Drug)
    • Eligibility criteria shortened, about 713 words
    • Secondary endpoints: 1 to 2
    • Study description shortened, about 789 words
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  41. Study sites: 96 to 97v59
  42. Study sites: 95 to 96v58
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Acute Myeloid Leukemia (AML)
1,203 trials monitored
See 65 trials at risk
Myelofibrosis
175 trials monitored
See 8 trials at risk
and 1 more disease
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Trial Details
NCT Number NCT02386800
Lead Sponsor Novartis Pharmaceuticals
Conditions Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
Enrollment 279 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov